Home   >  
Angiogenesis/Protein Tyrosine Kinase
  >  
Src/Bcr Abl
  >   Bosutinib Monohydrate
Bosutinib Monohydrate Chemical Structure

Bosutinib Monohydrate

Data Sheet For research use only. Not for human use.
Cat. No. :BCP17036CAS No. :918639-08-4Purity:98%
 Tel: 0086-17754423994   or   orders@biochempartner.com
Real-Time Inquiry ×

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Inquiry Online ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

Bulk Inquiry ×

* Required Fields.

Please complete the form below and we will contact you shortly.

Product name

 

* Applicant name

Catalog Number

 

* Institution/Company

* Email address

 

Phone number

Country

 

* Quantity Required

Remarks

  • Chemical Properties&Biological Activity
CAS No. 918639-08-4 Cat. No. BCP17036
Name Bosutinib Monohydrate
Synonyms SKI606; SKI 606; SK-I606;
SMILES
Chemical Name
Formula C26H31Cl2N5O4 M. Wt 548.46
Purity 98% Storage Store at 4-8°C
Description Bosutinib, also known as SKI-606, is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Bosutinib received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March, 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.
  • Quality Control&Technical Support
In the process of purchasing and using Biochempartner products, you can consult us if you have any problems: orders@biochempartner.com. We will try our best to solve all your doubts.

Recommend Products

More >

Tags:Bosutinib Monohydrate supplier,Bosutinib Monohydrate purchase,Bosutinib Monohydrate manufacturer,Bosutinib Monohydrate distributor,Bosutinib Monohydrate cost,Bosutinib Monohydrate buy,Bosutinib Monohydrate for sale

0086-13720134139